Clearmind Medicine Inc. (CMND) has taken a significant step forward in the treatment of addiction by filing a patent application for a groundbreaking combination therapy featuring Ibogaine and N-Acylethanolamines. This innovative therapy, developed in collaboration with SciSparc Ltd. (SPRC), combines the psychedelic compound Ibogaine with Palmitoylethanolamide (PEA), a member of the N-Acylethanolamines family. The goal of this combination is to enhance both the safety and efficacy of Ibogaine-based treatments.
Ibogaine, derived from the African shrub Tabernanthe iboga, has shown promising potential in addressing opioid, cocaine, and other substance use disorders. However, its use has not been without controversy, with reports of adverse effects and even fatalities related to Ibogaine ingestion. Clearmind Medicine’s innovative combination therapy aims to mitigate these risks while maximizing the therapeutic benefits of Ibogaine.
“The publication of this patent highlights Clearmind’s commitment to leadership in the psychedelics space through building a diverse patent portfolio, featuring technologies with varying timelines to market,” said Clearmind Medicine CEO Adi Zuloff-Shani. “Most importantly, we aim to provide safe and effective solutions for mental health conditions that currently have unmet needs.”
SciSparc, specializing in treatments targeting central nervous system disorders, brings valuable expertise to the collaboration. Their focus on cannabinoid-based therapeutics complements Clearmind’s work in psychedelic research. SciSparc’s experience in clinical-stage pharmaceuticals provides critical expertise in advancing the therapy.
Together, Clearmind and SciSparc are expanding the scope of their research to address a wider range of mental health issues. Their primary focus remains on developing safe and effective solutions for addiction. Clearmind Medicine’s intellectual property portfolio currently consists of 19 patent families and 29 granted patents, demonstrating their commitment to innovation and leadership in the field.
This patent filing signifies a major advancement in the treatment of mental health and substance use disorders. With the potential to improve the safety and efficacy of Ibogaine-based therapies, Clearmind Medicine’s combination therapy offers hope for individuals struggling with addiction and paves the way for a brighter future in mental health care.
